Stefan Suciu


Ontology type: schema:Person     


Person Info

NAME

Stefan

SURNAME

Suciu

Publications in SciGraph latest 50 shown

  • 2018-06-20 Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials in ANNALS OF HEMATOLOGY
  • 2017-09-19 Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials in LEUKEMIA
  • 2015-11-23 Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group in ANNALS OF HEMATOLOGY
  • 2015-10-12 Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials in ANNALS OF HEMATOLOGY
  • 2015-09-26 Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) in ANNALS OF HEMATOLOGY
  • 2015-09-24 Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG) in ANNALS OF HEMATOLOGY
  • 2015-06-08 IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951 in LEUKEMIA
  • 2014-11-17 High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT in BONE MARROW TRANSPLANTATION
  • 2014-08-07 Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies in ANNALS OF HEMATOLOGY
  • 2014-03-31 Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation in BONE MARROW TRANSPLANTATION
  • 2014-03-29 Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial) in ANNALS OF HEMATOLOGY
  • 2014-03-29 Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial in ANNALS OF HEMATOLOGY
  • 2013-09-25 An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions in LEUKEMIA
  • 2013-04-27 Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study) in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2012-03-31 Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups in ANNALS OF HEMATOLOGY
  • 2010-09-23 NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951 in LEUKEMIA
  • 2008-04 Sentinel lymph-node false positivity in melanoma in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2006-08-17 Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial in LEUKEMIA
  • 2005-09-08 Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group in LEUKEMIA
  • 2005-09-01 Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report in LEUKEMIA
  • 2005-08-04 Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups in LEUKEMIA
  • 2005-03-03 Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG in LEUKEMIA
  • 2003-05-01 The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921) in LEUKEMIA
  • 2003-01-01 The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial in LEUKEMIA
  • 2002-08-30 Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors in LEUKEMIA
  • 2001-11-01 Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine in LEUKEMIA
  • 2001 Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes in ACUTE LEUKEMIAS VIII
  • 2000-12-01 Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report in LEUKEMIA
  • 2000-10-24 High tPA-expression in primary melanoma of the limb correlates with good prognosis in BRITISH JOURNAL OF CANCER
  • 2000-06-06 What can we learn from phase II adjuvant trials in melanoma? in BRITISH JOURNAL OF CANCER
  • 1997-08-01 Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial in BONE MARROW TRANSPLANTATION
  • 1997 Postremission Therapy: The Role of Allogeneic Bone Marrow Transplantation in Acute Myelogenous Leukemia: An Analysis of the AML8A EORTC-GIMEMA Protocol in ACUTE LEUKEMIAS VI
  • 1996-03 Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group in ANNALS OF HEMATOLOGY
  • 1992-06 A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia in ANNALS OF HEMATOLOGY
  • 1992-04 A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia in ANNALS OF HEMATOLOGY
  • 1992-03 Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF) in INFECTION
  • 1991-02 The value of BMT in AML patients in first remission A statistician's view-point in ANNALS OF HEMATOLOGY
  • 1990 Dutch Childhood Leukemia Study Group: Early Results of Study ALL VI (1984–1988) in ACUTE LEUKEMIAS II
  • 1990 EORTC Leukemia Group Trials on Acute Myeloid Leukemias: An Overview in ACUTE LEUKEMIAS II
  • 1990 A Randomized Comparison of Intensive Maintenance Treatment for Adult Acute Myelogenous Leukemia Using Either Cyclic Alternating Drugs or Repeated Courses of the Induction-Type Chemotherapy: AML-6 Trial of the EORTC Leukemia Cooperative Group in ACUTE LEUKEMIAS II
  • 1987 Analysis of Clinical Trial Data in CLINICAL EVALUATION OF ANTITUMOR THERAPY
  • 1987 Therapy for Adolescent and Adult Acute Lymphoblastic Leukemia: Randomization of Induction and Consolidation Therapies (Preliminary Results of EORTC Study 58791) in ACUTE LEUKEMIAS
  • 1987 Treatment of Acute Lymphoblastic Leukemia in Children with the BFM Protocol: A Cooperative Study and Analysis of Prognostic Factors in ACUTE LEUKEMIAS
  • 1987 Addition of Rubidomycin to Induction Treatment with Vincristine, Prednisone, and l-Asparaginase in Standard-Risk Childhood Acute Lymphocytic Leukemia (Study ALL V): A Report on Behalf of the Dutch Childhood Leukemia Study Group in ACUTE LEUKEMIAS
  • 1986-02-01 Phase-II-study: Combination of cisplatinum, vindesine and dacarbazine in advanced malignant melanoma in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1986-02-01 A randomized phase-III-study on dtic, levamisole, and placebo as adjuvant treatment of high risk stage i primary helanoma in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1984 Estrogen Receptors and Distribution of Prognostic Factors in Primary Breast Cancer in CLINICAL INTEREST OF STEROID HORMONE RECEPTORS IN BREAST CANCER
  • 1983 The Value of the Ancillary Factor Scoring System in CANCER OF THE PROSTATE AND KIDNEY
  • 1983 Preliminary Results of Two Eortc Randomized Trials in Previously Untreated Patients with Advanced T3 — T4 Prostatic Cancer in CANCER OF THE PROSTATE AND KIDNEY
  • Affiliations

  • European Organisation for Research and Treatment of Cancer (current)
  • Institut Gustave Roussy
  • University Hospitals Birmingham NHS Foundation Trust
  • Antoni van Leeuwenhoek Hospital
  • VU Amsterdam
  • Leeds General Infirmary
  • University of Lausanne
  • Erasmus MC
  • Royal Surrey County Hospital
  • Essen University Hospital
  • Université Libre de Bruxelles
  • IRCCS Ospedale San Raffaele
  • Ghent University Hospital
  • Centre Hospitalier Universitaire de Reims
  • Amsterdam UMC Location VUmc
  • Ospedale Antonio Cardarelli
  • University of Leeds
  • York Hospital
  • Hôtel-Dieu de Paris
  • Huddersfield Royal Infirmary
  • Ferrarotto Hospital
  • KU Leuven
  • Centre Léon Bérard
  • University of Sydney
  • University of Birmingham
  • Sisters of Charity Hospital
  • Hôpital Pellegrin
  • University of Bordeaux
  • Policlinico Tor Vergata
  • Kiel University
  • Hôpital Édouard-Herriot
  • University of Nottingham
  • Leiden University Medical Center
  • Radboud University Nijmegen Medical Centre
  • University of Rome Tor Vergata
  • Specialised Hospital for Active Treatment of Oncology
  • Ospedale Regina Apostolorum
  • St.-Johannes-Hospital Dortmund
  • AZ Sint-Jan
  • Norwich University
  • Heidelberg University
  • University of Palermo
  • Heinrich Heine University Düsseldorf
  • Leibniz University Hannover
  • Universitätsklinikum Tübingen
  • University Hospital of Lausanne
  • Centre Hospitalier Universitaire de Toulouse
  • University Hospital of Zurich
  • University Hospital Centre Zagreb
  • Vrije Universiteit Brussel
  • European Institute of Oncology
  • Weston Park Cancer Centre
  • Hôpital d'Hautepierre
  • Hôpital Robert-Debré
  • Hôpital Cochin
  • Aarhus University Hospital
  • Nottingham City Hospital
  • University of Ulm
  • University Hospital
  • University of Freiburg
  • Haga Hospital
  • Royal Marsden Hospital
  • St James's University Hospital
  • Queen Fabiola Children's University Hospital
  • Centre Hospitalier Universitaire de Liège
  • TU Dresden
  • Institut Jules Bordet
  • University of Copenhagen
  • Universitair Ziekenhuis Leuven
  • Fondazione IRCCS Istituto Nazionale dei Tumori
  • University of Glasgow
  • McGill University
  • Royal Prince Alfred Hospital
  • Erasmus University Rotterdam
  • Charité - University Medicine Berlin
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.418936.1", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.14925.3b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412563.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.430814.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.12380.38", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418161.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.9851.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5645.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416224.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410718.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4989.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.18887.3e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410566.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.139510.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.16872.3a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413172.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.9909.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417375.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411394.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417789.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414867.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5596.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418116.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.1013.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6572.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412488.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414263.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412041.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413009.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.9764.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412180.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4563.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10419.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10417.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6530.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419285.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415756.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.459950.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.420036.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.261219.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7700.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10776.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411327.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.9122.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411544.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.8515.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411175.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412004.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412688.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.8767.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.15667.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417079.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412201.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413235.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411784.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.154185.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412920.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6582.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.449710.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5963.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413591.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.424926.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.443984.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412209.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411374.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4488.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418119.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5254.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417893.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.8756.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.14709.3b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413249.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6906.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6363.0", 
            "type": "Organization"
          }
        ], 
        "familyName": "Suciu", 
        "givenName": "Stefan", 
        "id": "sg:person.01014211567.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014211567.13"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-10-01T07:17", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/person/person_823.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01014211567.13'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01014211567.13'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01014211567.13'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01014211567.13'


     

    This table displays all metadata directly associated to this object as RDF triples.

    164 TRIPLES      10 PREDICATES      85 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01014211567.13 schema:affiliation Nd445d9e9f54e4384b3164cf61b4d706b
    2 grid-institutes:grid.1013.3
    3 grid-institutes:grid.10417.33
    4 grid-institutes:grid.10419.3d
    5 grid-institutes:grid.10776.37
    6 grid-institutes:grid.12380.38
    7 grid-institutes:grid.139510.f
    8 grid-institutes:grid.14709.3b
    9 grid-institutes:grid.14925.3b
    10 grid-institutes:grid.154185.c
    11 grid-institutes:grid.15667.33
    12 grid-institutes:grid.16872.3a
    13 grid-institutes:grid.18887.3e
    14 grid-institutes:grid.261219.f
    15 grid-institutes:grid.410566.0
    16 grid-institutes:grid.410569.f
    17 grid-institutes:grid.410718.b
    18 grid-institutes:grid.411175.7
    19 grid-institutes:grid.411327.2
    20 grid-institutes:grid.411374.4
    21 grid-institutes:grid.411394.a
    22 grid-institutes:grid.411544.1
    23 grid-institutes:grid.411784.f
    24 grid-institutes:grid.412004.3
    25 grid-institutes:grid.412041.2
    26 grid-institutes:grid.412180.e
    27 grid-institutes:grid.412201.4
    28 grid-institutes:grid.412209.c
    29 grid-institutes:grid.412488.3
    30 grid-institutes:grid.412563.7
    31 grid-institutes:grid.412688.1
    32 grid-institutes:grid.412920.c
    33 grid-institutes:grid.413009.f
    34 grid-institutes:grid.413172.2
    35 grid-institutes:grid.413235.2
    36 grid-institutes:grid.413249.9
    37 grid-institutes:grid.413591.b
    38 grid-institutes:grid.414263.6
    39 grid-institutes:grid.414867.8
    40 grid-institutes:grid.415756.4
    41 grid-institutes:grid.416224.7
    42 grid-institutes:grid.417079.c
    43 grid-institutes:grid.417375.3
    44 grid-institutes:grid.417789.4
    45 grid-institutes:grid.417893.0
    46 grid-institutes:grid.418116.b
    47 grid-institutes:grid.418119.4
    48 grid-institutes:grid.418161.b
    49 grid-institutes:grid.419285.3
    50 grid-institutes:grid.420036.3
    51 grid-institutes:grid.424926.f
    52 grid-institutes:grid.430814.a
    53 grid-institutes:grid.443984.6
    54 grid-institutes:grid.4488.0
    55 grid-institutes:grid.449710.f
    56 grid-institutes:grid.4563.4
    57 grid-institutes:grid.459950.4
    58 grid-institutes:grid.4989.c
    59 grid-institutes:grid.5254.6
    60 grid-institutes:grid.5596.f
    61 grid-institutes:grid.5645.2
    62 grid-institutes:grid.5963.9
    63 grid-institutes:grid.6363.0
    64 grid-institutes:grid.6530.0
    65 grid-institutes:grid.6572.6
    66 grid-institutes:grid.6582.9
    67 grid-institutes:grid.6906.9
    68 grid-institutes:grid.7700.0
    69 grid-institutes:grid.8515.9
    70 grid-institutes:grid.8756.c
    71 grid-institutes:grid.8767.e
    72 grid-institutes:grid.9122.8
    73 grid-institutes:grid.9764.c
    74 grid-institutes:grid.9851.5
    75 grid-institutes:grid.9909.9
    76 schema:familyName Suciu
    77 schema:givenName Stefan
    78 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014211567.13
    79 schema:sdDatePublished 2022-10-01T07:17
    80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    81 schema:sdPublisher N604ec7aebe334724b21c89e1db949e26
    82 sgo:license sg:explorer/license/
    83 sgo:sdDataset persons
    84 rdf:type schema:Person
    85 N604ec7aebe334724b21c89e1db949e26 schema:name Springer Nature - SN SciGraph project
    86 rdf:type schema:Organization
    87 Nd445d9e9f54e4384b3164cf61b4d706b schema:affiliation grid-institutes:grid.418936.1
    88 sgo:isCurrent true
    89 rdf:type schema:OrganizationRole
    90 grid-institutes:grid.1013.3 schema:Organization
    91 grid-institutes:grid.10417.33 schema:Organization
    92 grid-institutes:grid.10419.3d schema:Organization
    93 grid-institutes:grid.10776.37 schema:Organization
    94 grid-institutes:grid.12380.38 schema:Organization
    95 grid-institutes:grid.139510.f schema:Organization
    96 grid-institutes:grid.14709.3b schema:Organization
    97 grid-institutes:grid.14925.3b schema:Organization
    98 grid-institutes:grid.154185.c schema:Organization
    99 grid-institutes:grid.15667.33 schema:Organization
    100 grid-institutes:grid.16872.3a schema:Organization
    101 grid-institutes:grid.18887.3e schema:Organization
    102 grid-institutes:grid.261219.f schema:Organization
    103 grid-institutes:grid.410566.0 schema:Organization
    104 grid-institutes:grid.410569.f schema:Organization
    105 grid-institutes:grid.410718.b schema:Organization
    106 grid-institutes:grid.411175.7 schema:Organization
    107 grid-institutes:grid.411327.2 schema:Organization
    108 grid-institutes:grid.411374.4 schema:Organization
    109 grid-institutes:grid.411394.a schema:Organization
    110 grid-institutes:grid.411544.1 schema:Organization
    111 grid-institutes:grid.411784.f schema:Organization
    112 grid-institutes:grid.412004.3 schema:Organization
    113 grid-institutes:grid.412041.2 schema:Organization
    114 grid-institutes:grid.412180.e schema:Organization
    115 grid-institutes:grid.412201.4 schema:Organization
    116 grid-institutes:grid.412209.c schema:Organization
    117 grid-institutes:grid.412488.3 schema:Organization
    118 grid-institutes:grid.412563.7 schema:Organization
    119 grid-institutes:grid.412688.1 schema:Organization
    120 grid-institutes:grid.412920.c schema:Organization
    121 grid-institutes:grid.413009.f schema:Organization
    122 grid-institutes:grid.413172.2 schema:Organization
    123 grid-institutes:grid.413235.2 schema:Organization
    124 grid-institutes:grid.413249.9 schema:Organization
    125 grid-institutes:grid.413591.b schema:Organization
    126 grid-institutes:grid.414263.6 schema:Organization
    127 grid-institutes:grid.414867.8 schema:Organization
    128 grid-institutes:grid.415756.4 schema:Organization
    129 grid-institutes:grid.416224.7 schema:Organization
    130 grid-institutes:grid.417079.c schema:Organization
    131 grid-institutes:grid.417375.3 schema:Organization
    132 grid-institutes:grid.417789.4 schema:Organization
    133 grid-institutes:grid.417893.0 schema:Organization
    134 grid-institutes:grid.418116.b schema:Organization
    135 grid-institutes:grid.418119.4 schema:Organization
    136 grid-institutes:grid.418161.b schema:Organization
    137 grid-institutes:grid.418936.1 schema:Organization
    138 grid-institutes:grid.419285.3 schema:Organization
    139 grid-institutes:grid.420036.3 schema:Organization
    140 grid-institutes:grid.424926.f schema:Organization
    141 grid-institutes:grid.430814.a schema:Organization
    142 grid-institutes:grid.443984.6 schema:Organization
    143 grid-institutes:grid.4488.0 schema:Organization
    144 grid-institutes:grid.449710.f schema:Organization
    145 grid-institutes:grid.4563.4 schema:Organization
    146 grid-institutes:grid.459950.4 schema:Organization
    147 grid-institutes:grid.4989.c schema:Organization
    148 grid-institutes:grid.5254.6 schema:Organization
    149 grid-institutes:grid.5596.f schema:Organization
    150 grid-institutes:grid.5645.2 schema:Organization
    151 grid-institutes:grid.5963.9 schema:Organization
    152 grid-institutes:grid.6363.0 schema:Organization
    153 grid-institutes:grid.6530.0 schema:Organization
    154 grid-institutes:grid.6572.6 schema:Organization
    155 grid-institutes:grid.6582.9 schema:Organization
    156 grid-institutes:grid.6906.9 schema:Organization
    157 grid-institutes:grid.7700.0 schema:Organization
    158 grid-institutes:grid.8515.9 schema:Organization
    159 grid-institutes:grid.8756.c schema:Organization
    160 grid-institutes:grid.8767.e schema:Organization
    161 grid-institutes:grid.9122.8 schema:Organization
    162 grid-institutes:grid.9764.c schema:Organization
    163 grid-institutes:grid.9851.5 schema:Organization
    164 grid-institutes:grid.9909.9 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...